<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515624/" ref="ordinalpos=1879&amp;ncbi_uid=1479192&amp;link_uid=PMC2515624" image-link="/pmc/articles/PMC2515624/figure/F1/" class="imagepopup">Fig. 1. Simplified diagram of Hh <span class="highlight" style="background-color:">signaling</span>.  From: Implications of hedgehog <span class="highlight" style="background-color:">signaling</span> antagonists for cancer therapy. </a></div><br /><div class="p4l_captionBody">SMO is the key signal transducer in the Hh pathway. In the absence of Hh, the Hh receptor PTC can suppress SMO activity and repressor forms of Gli (GliR) are generated, leading to downregulation of Hh target genes. In the presence of Hh ligands (Shh, Ihh or Dhh), PTC is unable to affect SMO signaling. SMO somehow can promote formation of activated forms of Gli (GliA), resulting in upregulation of Hh target genes. Gene mutations (PTC, SMO) or abnormal over-expression of Hh ligands all can lead to elevated expression of Hh target genes.</div></div>